In one paragraphArticle in bioRxiv : the preprint server for biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
5 · Who and what moneyAuthors and funding
9 authors.
Kaan KumruDepartment of Pharmaceutical Chemistry, University of California San Francisco, San Francisco, CA, USA.ORCID 0000-0002-8015-0775 Zi YaoDepartment of Pharmaceutical Chemistry, University of California San Francisco, San Francisco, CA, USA.ORCID 0000-0003-1825-7472 Brandon B HolmesDepartment of Neurology, University of California, San Francisco, San Francisco, CA, USA.ORCID 0000-0002-1153-840X Fangzhu ZhaoDepartment of Pharmaceutical Chemistry, University of California San Francisco, San Francisco, CA, USA.ORCID 0000-0002-3172-1340 Yun ZhangDepartment of Pharmaceutical Chemistry, University of California San Francisco, San Francisco, CA, USA.
Emilio FerraraWeill Institute for Neurosciences, University of California, San Francisco, San Francisco, CA, USA.ORCID 0009-0002-4648-1885 Trenton M Peters-ClarkeDepartment of Pharmaceutical Chemistry, University of California San Francisco, San Francisco, CA, USA.
Kevin K LeungDepartment of Pharmaceutical Chemistry, University of California San Francisco, San Francisco, CA, USA.ORCID 0000-0002-2087-4974 James A WellsDepartment of Pharmaceutical Chemistry, University of California San Francisco, San Francisco, CA, USA.
Funding
Surfaceomic technologies and antibodies to probe cell surface proteomes and their interactomes at unprecedented small scale and high-resolutionR35GM122451 · NIGMS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI JAMES A WELLS · 2017 to 2026
$5.3MUCSF/UCB Joint Graduate Group in BioengineeringT32GM139794 · NIGMS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI DANIEL A FLETCHER, Christopher John Hernandez · 2021 to 2026
$5.2MResearch Training in Chemistry and Chemical BiologyT32GM145460 · NIGMS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Jason E Gestwicki · 2022 to 2026
$3.1MNew protein engineering-based tools and technologies for characterizing cell surface proteolysis in cancer cells for novel neo-epitope biomarkers and drug targetsR01CA248323 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI JAMES A WELLS · 2020 to 2026
$2.6MInterrogating and Targeting Microglia Phagocytosis in Alzheimer’s DiseaseK08NS133290 · NINDS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Brandon Blake Holmes · 2023 to 2026
$837kToward Understanding the Functional Landscape of Proteolysis at the Cell SurfaceF32CA298768 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Trenton Peters-Clarke · 2025 to 2026
$155kNCI NIH HHS F32 CA298768NCI NIH HHS R01 CA248323NIGMS NIH HHS R35 GM122451NIGMS NIH HHS T32 GM139794NIGMS NIH HHS T32 GM145460NINDS NIH HHS K08 NS133290
6 · The paper itselfAbstract
Extracellular targeted protein degradation (eTPD) is as an important new modality for manipulating the extracellular proteome. However, most eTPD receptors are expressed broadly or are restricted to the liver. Cytokine receptor targeting chimeras (kineTACs) are genetically encoded bispecifics for eTPD that fuse a natural ligand like CXCL12 to an antibody, directing soluble or membrane proteins for lysosomal degradation using the widely expressed chemokine receptor CXCR7 (Pance K, Gramespacher JA., Byrnes, JR, Salangsang F., Serrano JAC, Cotton AD, Steri V, and Wells JA,
Identifiers
PMID40949987
PMCPMC12424666
What Socratic holds
Textmetadata
LicenceCC BY
Read underepoch 390